OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable efficacy and safety profile with the reference product XOLAIR® (omalizumab)[1] The...
Hence then, the article about u s fda approves celltrion s omlyclo omalizumab igec as the first and only biosimilar with interchangeability designation referencing xolair was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR® )
Also on site :
- UN renews Sudan ceasefire appeal over ‘unimaginable suffering’ of civilians
- Central African Republic election: Who’s running and what’s at stake?
- Israeli forces continue ceasefire violations with attacks across Gaza